

ATAGI recommendation for using of DT5aP-HBV-IPV-Hib(PRP-OMP) vaccine versus DT3aP-HBV-IPV-Hib(PRP-TT) vaccine for primary vaccination in infants and children aged 6 months to 10 years

There is no preferential recommendation between the use of DT5aP-HBV-IPV-Hib(PRP-OMP) vaccine (Vaxelis) and DT3aP-HBV-IPV-Hib(PRP-TT) vaccine (Infanrix hexa) for primary vaccination in infants and children aged 6 months to 10 years.

Justification

- Vaxelis demonstrates little or no difference in immunogenicity compared to Infanrix hexa, at both one month after the primary infant course, and at 13 months of age.
- Vaxelis demonstrates little or no difference in the frequency or severity of adverse events following immunisation compared to Infanrix hexa.
- The differences between the preparation required to administer Vaxelis and that for Infanrix hexa are likely to be acceptable to key stakeholders.